ArticleEBioMedicine2020

BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer.

Goldie Y L Lui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.